Cargando…

TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks

53BP1 promotes nonhomologous end joining (NHEJ) over homologous recombination (HR) repair by mediating inactivation of DNA end resection. Ubiquitination plays an important role in regulating dissociation of 53BP1 from DNA double-strand breaks (DSBs). However, how this process is regulated remains po...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jian, Zhou, Yingke, Pan, Penglin, Yu, Haixin, Wang, Zixi, Li, Lei Lily, Wang, Bing, Yan, Yuqian, Pan, Yunqian, Ye, Qi, Liu, Tianjie, Feng, Xiaoyu, Xu, Shan, Wang, Ke, Wang, Xinyang, Jian, Yanlin, Ma, Bohan, Fan, Yizeng, Gao, Yang, Huang, Haojie, Li, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066190/
https://www.ncbi.nlm.nih.gov/pubmed/37002234
http://dx.doi.org/10.1038/s41467-023-37499-5
Descripción
Sumario:53BP1 promotes nonhomologous end joining (NHEJ) over homologous recombination (HR) repair by mediating inactivation of DNA end resection. Ubiquitination plays an important role in regulating dissociation of 53BP1 from DNA double-strand breaks (DSBs). However, how this process is regulated remains poorly understood. Here, we demonstrate that TRABID deubiquitinase binds to 53BP1 at endogenous level and regulates 53BP1 retention at DSB sites. TRABID deubiquitinates K29-linked polyubiquitination of 53BP1 mediated by E3 ubiquitin ligase SPOP and prevents 53BP1 dissociation from DSBs, consequently inducing HR defects and chromosomal instability. Prostate cancer cells with TRABID overexpression exhibit a high sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors. Our work shows that TRABID facilitates NHEJ repair over HR during DNA repair by inducing prolonged 53BP1 retention at DSB sites, suggesting that TRABID overexpression may predict HR deficiency and the potential therapeutic use of PARP inhibitors in prostate cancer.